Whalen Wealth Management Inc. Invests $224,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)

Whalen Wealth Management Inc. purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 19,401 shares of the company’s stock, valued at approximately $224,000.

Other institutional investors have also recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Roivant Sciences in the second quarter valued at approximately $34,000. Gladius Capital Management LP acquired a new stake in Roivant Sciences during the 3rd quarter valued at $35,000. Point72 Hong Kong Ltd bought a new position in Roivant Sciences in the 2nd quarter valued at $36,000. US Bancorp DE boosted its stake in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Roivant Sciences during the second quarter worth $53,000. 64.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. Bank of America lifted their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Stock Down 0.4 %

Shares of Roivant Sciences stock opened at $11.16 on Tuesday. The business has a fifty day simple moving average of $11.75 and a 200 day simple moving average of $11.32. The stock has a market cap of $8.25 billion, a PE ratio of 1.98 and a beta of 1.24. Roivant Sciences Ltd. has a 12 month low of $8.56 and a 12 month high of $13.06.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the sale, the chief operating officer now owns 617,470 shares of the company’s stock, valued at $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the transaction, the chief accounting officer now owns 209,322 shares in the company, valued at $2,488,838.58. This trade represents a 54.43 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,577,309 shares of company stock worth $42,151,184. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.